What happens when you hit three metabolic targets at once? Researchers are finding out — and the early numbers are hard to ignore.
If you’ve been following the GLP-1 space, you already know the story arc: semaglutide (Ozempic/Wegovy) shocked the world with 15% average weight loss, then tirzepatide (Mounjaro/Zepbound) came along and pushed that to 20%+. Now there’s a new compound in clinical trials that’s being called the most powerful metabolic drug ever tested in humans.
Meet retatrutide — and if the Phase 2 data holds up, it might make everything before it look like a warmup.
What Is Retatrutide (GLP-3) ?
Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly — the same company behind tirzepatide. But while tirzepatide hits two receptors (GLP-1 and GIP), retatrutide adds a third: the glucagon receptor.
That makes it a triple agonist: GLP-1 / GIP / glucagon.
Here’s what each arm does:
- GLP-1 (glucagon-like peptide-1): Slows gastric emptying, reduces appetite, improves insulin sensitivity. This is the core of Ozempic’s mechanism.
- GIP (glucose-dependent insulinotropic polypeptide): Enhances fat metabolism and works synergistically with GLP-1 to amplify the weight loss signal.
- Glucagon receptor: This is the curveball. Glucagon normally raises blood sugar — but when activated at the right dose alongside GLP-1 and GIP, it appears to dramatically boost fat burning and energy expenditure.
The idea is that glucagon’s thermogenic effect — burning more calories even at rest — offsets its blood sugar-raising properties when paired with the other two agonists. Whether that balance holds long-term is one of the things trials are testing.
The Phase 2 Numbers
The Phase 2 trial results, published in The New England Journal of Medicine in 2023, sent the obesity medicine world into overdrive.
After 48 weeks, participants on the highest dose of retatrutide (12 mg weekly) lost an average of 24.2% of their body weight. Some individuals lost over 30%.
To put that in perspective:
- Semaglutide (Wegovy): ~15% average weight loss
- Tirzepatide (Zepbound): ~20–22% average weight loss
- Retatrutide: ~24% average weight loss (Phase 2, highest dose)
The trial also showed improvements in cardiometabolic markers — blood pressure, triglycerides, waist circumference — and notably, the weight loss curve hadn’t plateaued by week 48. That suggests there may be room for even greater losses with longer treatment.
Why the Biohacking Community Is Paying Attention
Beyond raw weight loss numbers, a few things about retatrutide’s mechanism stand out for people interested in metabolic optimization:
1. It may actually raise metabolic rate. Most weight loss interventions slow your metabolism as you lose weight — the body fights back. Glucagon receptor agonism appears to counteract this by increasing energy expenditure. That’s a meaningful difference from simply suppressing appetite.
2. Fat loss vs. muscle loss. One of the biggest knocks on GLP-1 drugs is that a significant portion of weight lost is lean mass. Retatrutide’s Phase 2 data suggests a favorable fat-to-muscle loss ratio, though this needs more rigorous characterization in Phase 3.
3. Liver fat. Early signals show significant reductions in hepatic fat — relevant for anyone dealing with metabolic syndrome, NAFLD, or insulin resistance.
4. Lipid profiles. Triglycerides dropped substantially in the trial, and there were improvements in HDL — markers that matter for cardiovascular risk and for athletes thinking about long-term health.
What We Don’t Know Yet
Phase 2 trials are designed to assess safety signals and find the right dose — not to prove long-term efficacy. Here’s what’s still open:
Side effects at high doses. Nausea and GI distress are common across this drug class. At the 12 mg dose, a meaningful portion of participants experienced GI side effects, though most were rated mild to moderate. The glucagon component also adds complexity — managing blood sugar carefully matters.
Long-term safety. GLP-1 drugs have raised questions about thyroid C-cell effects and pancreatitis risk (mostly in rodent models, not confirmed in humans at scale). Adding a glucagon agonist introduces new variables that longer trials will need to address.
Muscle preservation at scale. The lean mass data is encouraging but limited. Phase 3 trials with larger populations and longer follow-up will tell the real story — especially for active people who care about body composition, not just the number on the scale.
What happens when you stop. Rebound weight gain after discontinuing GLP-1/GIP drugs is well documented. There’s no reason to think retatrutide will be different, and this is one of the central challenges the field hasn’t solved.
Where It Stands Now
As of 2024, retatrutide is in Phase 3 clinical trials. Eli Lilly is running multiple large-scale studies — including one focused specifically on cardiovascular outcomes (similar to the SURMOUNT-CVOT trials for tirzepatide). If those go well, a regulatory submission could come in 2025–2026, with potential approval not long after.
It won’t be cheap. Branded GLP-1 drugs currently run $900–$1,300/month without insurance in the US. Retatrutide, if anything, will likely be priced comparably or higher at launch.
The Bottom Line
Retatrutide is the most promising compound in the metabolic drug pipeline — not just for people with obesity, but potentially for anyone interested in how the body manages fat, energy, and metabolic health. The triple-agonist mechanism is genuinely novel, and the Phase 2 efficacy data is unlike anything seen before in a pharmaceutical context.
That said, Phase 2 is not Phase 3. History is littered with drugs that looked extraordinary in early trials and ran into trouble at scale. The next couple of years of data will be definitive.
For now, it’s worth understanding the science — because this drug class, with or without retatrutide specifically, is going to reshape how medicine thinks about obesity, metabolic disease, and possibly aging-adjacent biology for the next decade.
This post is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not currently approved for clinical use.
